Mirati Therapeutics, Inc.
(NASDAQ : MRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.01%296.831.4%$601.48m
AMGNAmgen, Inc.
0.32%236.741.3%$495.31m
GILDGilead Sciences, Inc.
-2.75%65.771.0%$370.34m
REGNRegeneron Pharmaceuticals, Inc.
1.15%376.422.6%$305.23m
VRTXVertex Pharmaceuticals, Inc.
-0.71%218.981.9%$275.99m
ILMNIllumina, Inc.
0.85%324.723.5%$241.12m
CLVSClovis Oncology, Inc.
-4.24%12.8614.7%$219.13m
SRPTSarepta Therapeutics, Inc.
31.43%132.0514.6%$207.70m
ALXNAlexion Pharmaceuticals, Inc.
-1.82%110.422.0%$199.61m
ARWRArrowhead Pharmaceuticals, Inc.
-1.28%66.4611.4%$199.52m
AAgilent Technologies, Inc.
-1.30%83.711.6%$164.84m
EXASEXACT Sciences Corp.
2.08%87.2024.0%$164.17m
BLUEbluebird bio, Inc.
6.78%89.7514.2%$152.73m
GBTGlobal Blood Therapeutics, Inc.
-0.01%76.886.0%$140.08m
BOLDAudentes Therapeutics, Inc.
0.05%59.401.4%$136.27m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.